ClinicalTrials.govpublic full text
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
multiple myeloma, autologous hematopoietic cell transplantation (hct), high-dose melphalan, selinexor, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 880624
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.